XML 39 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
Financial Instruments
12 Months Ended
Dec. 31, 2013
Financial Instruments

Note 18—Financial instruments:

The following table summarizes the valuation of our short-term investments and financial instruments by the ASC Topic 820 categories as of December 31, 2012 and 2013:

 

 

Fair Value Measurements

 

 

Total

 

  

Quoted
Prices in
Active
Markets
(Level 1)

 

  

Significant
Other
Observable
Inputs
(Level 2)

 

  

Significant
Unobservable
Inputs
(Level 3)

 

 

(In millions)

 

Asset (liability)

 

 

 

  

 

 

 

  

 

 

 

  

 

 

 

December 31, 2012:

 

 

 

  

 

 

 

  

 

 

 

  

 

 

 

Marketable securities:

 

 

 

  

 

 

 

  

 

 

 

  

 

 

 

Current

$

.9

  

  

$

—  

  

  

$

.9

  

  

$

—  

  

Noncurrent

 

256.8

  

  

 

3.5

  

  

 

3.3

  

  

 

250.0

  

Currency forward contracts

 

1.8

  

  

 

1.8

  

  

 

—  

  

  

 

—  

  

December 31, 2013:

 

 

 

  

 

 

 

  

 

 

 

  

 

 

 

Marketable securities:

 

 

 

  

 

 

 

  

 

 

 

  

 

 

 

Current

$

3.8

  

  

$

2.4

  

  

$

1.4

  

  

$

—  

  

Noncurrent

 

253.3

  

  

 

1.4

  

  

 

1.9

  

  

 

250.0

  

Currency forward contracts

 

(1.0

)  

  

 

(1.0

)  

  

 

—  

  

  

 

—  

  

See Note 4 for information on how we determine the fair value of our marketable securities.

Certain of our sales generated by Chemicals Segment’s non-U.S. operations are denominated in U.S. dollars. Our Chemicals Segment periodically uses currency forward contracts to manage a very nominal portion of currency exchange rate risk associated with trade receivables denominated in a currency other than the holder’s functional currency or similar exchange rate risk associated with future sales. We have not entered into these contracts for trading or speculative purposes in the past, nor do we currently anticipate entering into such contracts for trading or speculative purposes in the future. Derivatives used to hedge forecasted transactions and specific cash flows associated with financial assets and liabilities denominated in currencies other than the U.S. dollar and which meet the criteria for hedge accounting are designated as cash flow hedges. Consequently, the effective portion of gains and losses is deferred as a component of accumulated other comprehensive income (loss) and is recognized in earnings at the time the hedged item affects earnings. Contracts that do not meet the criteria for hedge accounting are marked-to-market at each balance sheet date with any resulting gain or loss recognized in income currently as part of net currency transactions. The fair value of the currency forward contracts is determined using Level 1 inputs based on the currency spot forward rates quoted by banks or currency dealers.

At December 31, 2013, Kronos had currency forward contracts to exchange:

·

an aggregate of $36.0 million for an equivalent value of Canadian dollars at an exchange rate ranging from Cdn. $1.02 to Cdn. $1.06 per U.S. dollar.  These contracts with Wells Fargo Bank, N.A. mature from January 2014 through December 2014 at a rate of $3.0 million per month, subject to early redemption provisions at our option;

·

an aggregate $20.0 million for an equivalent value of Norwegian kroner at exchange rates ranging from kroner 6.12 to kroner 6.25 per U.S. dollar.  These contracts with DnB Nor Bank ASA mature at a rate of $5.0 million per month in certain months from January 2014 through October 2014; and

·

an aggregate €20.0 million for an equivalent value of Norwegian kroner at exchange rates ranging from kroner 8.04 to kroner 8.41 per euro.  These contracts with DnB Nor Bank ASA mature at a rate of €5.0 million per month in certain months from January 2014 through October 2014.

The estimated fair value of such currency forward contracts at December 31, 2013 was a $1.0 million net liability of which $.2 million is recognized as part of accounts and other receivables and $1.2 million is recognized as part of accounts payable and accrued liabilities in our Consolidated Balance Sheet with a corresponding $1.0 million currency transaction loss in our Consolidated Statement of Operations, (2012—$1.8 million net asset, recognized as part of accounts and other receivables with a corresponding $1.8 million currency transaction gain in our Consolidated Statement of Operations). We did not use hedge accounting for any of our contracts to the extent we held such contracts during 2011, 2012 and 2013.

The following table presents the financial instruments that are not carried at fair value but which require fair value disclosure as of December 31, 2012 and 2013:

 

 

December 31,

 

 

2012 

 

  

2013

 

 

Carrying
amount

 

  

Fair
value

 

  

Carrying
amount

 

  

Fair
value

 

 

(In millions)

 

Cash, cash equivalents and restricted cash equivalents

$

395.9

  

  

$

395.9

  

  

$

186.8

  

  

$

186.8

  

Deferred payment obligation

 

—  

 

 

 

—  

 

 

 

8.2

 

 

 

8.2

 

Long-term debt (excluding capitalized leases):

 

 

 

  

 

 

 

  

 

 

 

  

 

 

 

Kronos note payable to Contran

$

—  

  

  

$

 —  

  

  

$

170.0

  

  

$

170.0

  

Kronos term loan

 

384.5

  

  

 

396.8

  

  

 

 —  

  

  

 

 —  

  

Snake River Sugar Company fixed rate loans

 

250.0

  

  

 

250.0

  

  

 

250.0

  

  

 

250.0

  

WCS fixed rate debt

 

77.1

  

  

 

77.1

  

  

 

72.4

  

  

 

72.4

  

Valhi Contran credit facility

 

157.6

  

  

 

157.6

  

  

 

206.5

  

  

 

206.5

  

Kronos variable rate bank credit facilities

 

13.2

  

  

 

13.2

  

  

 

11.1

  

  

 

11.1

  

CompX variable rate promissory note

 

18.5

  

  

 

18.5

  

  

 

 —  

  

  

 

 —  

  

Tremont promissory note

 

—  

  

  

 

—  

  

  

 

19.1

  

  

 

19.1

  

BMI bank note payable

 

—  

  

  

 

—  

  

  

 

11.2

  

  

 

11.2

  

Landwell note payable to the City of Henderson

 

—  

  

  

 

—  

  

  

 

3.1

  

  

 

3.1

  

Noncontrolling interest in:

 

 

 

  

 

 

 

  

 

 

 

  

 

 

 

Kronos common stock

$

267.0

  

  

$

442.6

  

  

$

241.9

  

  

$

431.6

  

NL common stock

 

77.8

  

  

 

94.8

  

  

 

74.5

  

  

 

92.6

  

CompX common stock

 

13.3

  

  

 

23.4

  

  

 

13.6

  

  

 

23.1

  

Valhi stockholders’ equity

$

733.6

  

  

$

4,238.9

  

  

$

601.3

  

  

$

5,961.7

  

The fair value of our publicly-traded marketable securities, noncontrolling interest in NL, Kronos and CompX and our common stockholders’ equity are all based upon quoted market prices, Level 1 inputs at each balance sheet date. At December 31, 2012, the estimated market price of Kronos’ term loan was $1,017.5 per $1,000 principal amount. The fair value of the 6 term loan was based on quoted market prices; however, these quoted market prices represent Level 2 inputs because the markets in which the term loan trade were not active. The fair value of our fixed-rate nonrecourse loans from Snake River Sugar Company is based upon the $250 million redemption price of our investment in the Amalgamated Sugar Company LLC, which collateralizes the nonrecourse loans, (this is a Level 3 input). Fair values of variable interest rate notes receivable and debt and other fixed-rate debt are deemed to approximate book value. Due to their near-term maturities, the carrying amounts of accounts receivable and accounts payable are considered equivalent to fair value. See Notes 4 and 9.